Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (AMPH)
NASDAQ:AMPH
RESEARCH TOOLSreports
Holding AMPH?
Track your performance easily
Earnings Data
Report Date
Mar 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.96Last Year’s EPS
$0.88Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -26.70%
|Next Earnings Date:Mar 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presents a mixed picture with notable achievements in revenue growth and new product launches, but is offset by challenges such as increased competition, supply disruptions, and decreased net income.Company Guidance
During the third quarter earnings call for Amphastar Pharmaceuticals, the company provided guidance on several key metrics and strategic initiatives. Amphastar reported net revenues of $191.2 million, a 6% increase compared to the same period last year, despite disruptions caused by Hurricane Helene. Primatene MIST achieved record quarterly sales of $26 million, contributing significantly to the company's goal of reaching $100 million in annual sales for this product by the end of 2024. Additionally, the transition of BAQSIMI sales, which amounted to $40.4 million, is progressing smoothly, with plans to expand the sales force to enhance market presence. However, the glucagon market saw a 9% decline in sales to $26.7 million due to increased competition. Amphastar also launched its albuterol MDI product, signaling growth in its respiratory portfolio. On the regulatory front, discussions with the FDA for AMP-002 are ongoing, with hopes for a clear approval path soon, while AMP-015 and AMP-018 are on track for future filings. The company continues to focus on expanding its biosimilar pipeline, with AMP-028 being a noteworthy addition, as it aims to leverage its expertise for sustainable growth.Revenue Growth
Amphastar reported net revenues of $191.2 million, marking a 6% increase year-over-year.
Primatene MIST Sales Record
Primatene MIST achieved its highest quarterly sales since launch, reaching $26 million.
Expansion in Diabetes Portfolio
The GLP-1 ANDA, AMP-018, was granted competitive generic therapeutic designation and priority review.
New Product Launch
Launch of albuterol MDI product in Q3 2024, expanding the respiratory portfolio.
Pipeline Expansion
Introduction of AMP-028, a new biosimilar addition with IQVIA sales of $2 billion and no current biosimilars.
---
AMPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AMPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $53.40 | $46.09 | -13.69% |
| Aug 07, 2024 | $38.89 | $44.06 | +13.29% |
| May 08, 2024 | $42.21 | $42.43 | +0.52% |
| Feb 28, 2024 | $54.74 | $46.57 | -14.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Amphastar Pharmaceuticals (AMPH) report earnings?
Amphastar Pharmaceuticals (AMPH) is schdueled to report earning on Mar 12, 2025, TBA Not Confirmed.
What is Amphastar Pharmaceuticals (AMPH) earnings time?
Amphastar Pharmaceuticals (AMPH) earnings time is at Mar 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMPH EPS forecast?
AMPH EPS forecast for the fiscal quarter 2024 (Q4) is $0.96.
---